IL94991A - Steroidal enzyme inhibitors and/or androgen receptor antagonists their preparation and pharmaceutical compositions for the treatment of androgen related diseases - Google Patents

Steroidal enzyme inhibitors and/or androgen receptor antagonists their preparation and pharmaceutical compositions for the treatment of androgen related diseases

Info

Publication number
IL94991A
IL94991A IL9499190A IL9499190A IL94991A IL 94991 A IL94991 A IL 94991A IL 9499190 A IL9499190 A IL 9499190A IL 9499190 A IL9499190 A IL 9499190A IL 94991 A IL94991 A IL 94991A
Authority
IL
Israel
Prior art keywords
inhibitor
alkyl
group
hydrogen
antiandrogen
Prior art date
Application number
IL9499190A
Other languages
English (en)
Other versions
IL94991A0 (en
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23486146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL94991(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of IL94991A0 publication Critical patent/IL94991A0/xx
Publication of IL94991A publication Critical patent/IL94991A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL9499190A 1989-07-07 1990-07-06 Steroidal enzyme inhibitors and/or androgen receptor antagonists their preparation and pharmaceutical compositions for the treatment of androgen related diseases IL94991A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37671089A 1989-07-07 1989-07-07

Publications (2)

Publication Number Publication Date
IL94991A0 IL94991A0 (en) 1991-06-10
IL94991A true IL94991A (en) 1999-11-30

Family

ID=23486146

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9499190A IL94991A (en) 1989-07-07 1990-07-06 Steroidal enzyme inhibitors and/or androgen receptor antagonists their preparation and pharmaceutical compositions for the treatment of androgen related diseases

Country Status (17)

Country Link
US (2) US5593981A (da)
EP (1) EP0595796B1 (da)
JP (1) JP3350048B2 (da)
KR (1) KR920703065A (da)
AT (1) ATE230994T1 (da)
AU (1) AU5851690A (da)
CA (1) CA2062792C (da)
DE (1) DE69034035T2 (da)
DK (1) DK0595796T3 (da)
ES (1) ES2189784T3 (da)
HU (1) HUT60139A (da)
IE (1) IE902458A1 (da)
IL (1) IL94991A (da)
MY (1) MY106725A (da)
NZ (2) NZ234417A (da)
WO (1) WO1991000733A1 (da)
ZA (1) ZA905313B (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5143909A (en) * 1991-03-19 1992-09-01 Merrell Dow Pharmaceuticals Inc. Aminosteroids in a method for inhibiting c17-20 lyase
IL101245A0 (en) * 1991-03-20 1992-11-15 Merck & Co Inc Pharmaceutical compositions for the treatment of prostatic cancer
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
US5994362A (en) * 1992-03-11 1999-11-30 Merck & Co., Inc. Method of treatment for prostatic cancer
SK286051B6 (sk) * 1993-01-19 2008-02-05 Endorecherche Inc. Použitie prekurzora pohlavného steroidu na prípravu liečiva na prevenciu alebo liečenie znížených alebo nevyrovnaných koncentrácií pohlavných steroidov
DE4318371A1 (de) * 1993-05-28 1994-12-01 Schering Ag Mittel, enthaltend eine Verbindung mit antiandrogener sowie eine Verbindung mit kompetitiver, progesteronantagonistischer Wirkung
US5637310A (en) * 1993-12-20 1997-06-10 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
EP0748220A4 (en) * 1994-01-21 1997-09-10 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
DE19610645A1 (de) * 1996-03-06 1997-09-11 Schering Ag Kombination von Dehydroepiandrosteron und Aromatasehemmern und Verwendung dieser Kombination zur Herstellung eines Arzeimittels zur Behandlung eines relativen und absoluten Androgenmangels beim Mann
EP1321146A3 (en) * 1998-03-11 2004-06-02 Endorecherche Inc. Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
JP2002506077A (ja) 1998-03-11 2002-02-26 アンドルシェルシュ・インコーポレイテッド タイプ５およびタイプ３１７β−ヒドロキシステロイドデヒドロゲナーゼのインヒビターおよびその使用法
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6165504A (en) * 1998-09-23 2000-12-26 Barr Laboratories, Inc. Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US6613758B1 (en) 1999-04-02 2003-09-02 Barr Laboratories, Inc. Method for treating osteoporosis in castrated prostatic cancer patients
CA2386095A1 (en) 1999-09-30 2001-04-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
JP3908162B2 (ja) 2000-06-30 2007-04-25 中外製薬株式会社 新規な抗アンドロゲン剤
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2002089802A2 (en) 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
RU2315763C2 (ru) 2001-09-06 2008-01-27 Шеринг Корпорейшн Соединение и фармацевтическая композиция
CN1571782A (zh) 2001-10-17 2005-01-26 先灵公司 作为3型17β－羟基类固醇脱氢酶抑制剂用于治疗雄激素依赖疾病的哌啶乙酰胺类化合物和哌嗪乙酰胺类化合物
US20040096510A1 (en) * 2001-11-29 2004-05-20 Steiner Mitchell S. Prevention and treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
PT1666033E (pt) * 2001-11-29 2009-02-09 Gtx Inc Prevenção e tratamento de osteoporose induzida pela falta de androgénio
ATE485818T1 (de) * 2002-07-30 2010-11-15 Karykion Inc Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
PE20040750A1 (es) 2002-11-18 2004-11-06 Schering Corp Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3
CA2509758A1 (en) 2002-12-17 2004-07-22 Schering Corporation 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
WO2004089304A2 (en) 2003-04-01 2004-10-21 Hollis-Eden Pharmaceuticals, Inc. Antiandrogens with marginal agonist activity and methods of use
DK1802312T3 (da) 2004-10-20 2015-12-14 Endorech Inc Kønssteroidudgangsstof i kombination med en selektiv østrogenreceptormodulator til forebyggelse og behandling af vaginal atrofi i postmenopausale kvinder
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
SI2450041T1 (sl) 2005-10-12 2019-02-28 Unimed Pharmaceuticals, Llc Izboljšan testosteronski gel za uporabo pri zdravljenju hipogonadizma
US20070141581A1 (en) * 2005-12-15 2007-06-21 University Of North Texas Health Science Center At Fort Worth Membrane androgen receptor as a therapeutic target for the prevention/promotion of cell death
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
US8354396B2 (en) * 2006-11-17 2013-01-15 Harbor Therapeutics, Inc. Drug identification and treatment method
US20080221074A1 (en) * 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
US20080153792A1 (en) * 2006-11-17 2008-06-26 Frincke James M Drug Identification and Treatment Method
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
EP2150256A4 (en) * 2007-05-03 2010-04-28 Univ Yale LOCAL ACTIVE, SOFT ANTIANDROGENE
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound
US20100222315A1 (en) * 2008-09-24 2010-09-02 Harbor BioSciencs, Inc. Patient populations and treatment methods
US20100227841A1 (en) * 2008-09-24 2010-09-09 Harbor BioSciencs, Inc. Patient populations and treatment methods
WO2010036822A1 (en) * 2008-09-24 2010-04-01 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
SG178403A1 (en) * 2009-08-14 2012-03-29 Opko Health Inc Intravenous formulations of neurokinin-1 antagonists
US20110129423A1 (en) * 2009-11-30 2011-06-02 Frincke James M Anticancer compounds and screening method
CN115505019B (zh) * 2022-11-07 2024-01-26 南宁师范大学 7-酰胺取代雌甾类化合物及其制备方法和应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161540A (en) * 1966-08-22 1979-07-17 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US3995060A (en) * 1972-06-20 1976-11-30 Schering Corporation Antiandrogenic agents and method for the treatment of androgen dependent disease states
FR2277082A1 (fr) * 1974-07-04 1976-01-30 Roussel Uclaf Nouveaux heptenes derives de la testosterone, leur procede de preparation et leur application a la fabrication d'antigenes
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US4329364A (en) * 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
GR60362B (en) * 1975-06-25 1978-05-19 Leo Pharm Prod Ltd Preparation process of new 16-ethers of fusidic acid derivatives
IE44263B1 (en) * 1975-12-03 1981-09-23 Leo Pharm Prod Ltd New fusidic acid derivatives
US4087461A (en) * 1976-02-26 1978-05-02 The Johns Hopkins University Anti-androgenic steroids
DE2617646C2 (de) * 1976-04-22 1986-07-31 Hoechst Ag, 6230 Frankfurt Nonapeptid-amide und Decapeptid-amide mit Gonadoliberin-Wirkung, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
US4055641A (en) * 1976-05-10 1977-10-25 Richardson-Merrell Inc. Method of treating benign prostatic hypertrophy
GB1524747A (en) * 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4139638A (en) * 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
US4191759A (en) * 1978-04-13 1980-03-04 Merck & Co., Inc. N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
NZ207413A (en) * 1979-03-05 1984-11-09 Wisconsin Alumni Res Found Steroid intermediates in the preparation of 24,24-difluoro-25-hydroxy-vitamin d3
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
NZ197008A (en) * 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
FR2528434B1 (fr) * 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
US4347363A (en) * 1981-09-17 1982-08-31 Sterling Drug Inc. Process for preparing 1,2-dihydro-6-methyl-2-oxo-5-(pyridinyl)nicotinonitriles
US4481190A (en) * 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
DE3339295A1 (de) * 1982-11-15 1984-05-17 Schering AG, 1000 Berlin und 4709 Bergkamen 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung
GR79447B (da) * 1982-12-31 1984-10-30 Mortimer Christopher H Dr
GB8311678D0 (en) * 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
ES8502612A1 (es) * 1983-06-15 1985-02-01 Schering Ag Procedimiento para la preparacion de 13a-alquilgonanos
GB8327256D0 (en) * 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8410901D0 (en) * 1984-04-27 1984-06-06 Ici Plc Phenol derivatives
GB8410899D0 (en) * 1984-04-27 1984-06-06 Ici Plc Phenol derivatives
IE58417B1 (en) * 1984-04-27 1993-09-22 Ici Plc Chemical derivatives
US5053403A (en) * 1984-05-11 1991-10-01 Norman Orentreich Methods for treatment of male-pattern baldness
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US5064813A (en) * 1984-08-02 1991-11-12 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
IE58836B1 (en) * 1984-08-02 1993-11-17 Labrie Fernand Pharmaceutical composition for combination therapy of hormone dependent cancers
US5023234A (en) * 1985-02-08 1991-06-11 Fernand Labrie Combination male breast cancer therapy
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
ATE43499T1 (de) * 1984-10-10 1989-06-15 Ile De France Synergistische empfaengnisverhuetende mischung.
EP0188010A1 (en) * 1985-01-14 1986-07-23 Gist-Brocades N.V. New process for the preparation of certain steroids, especially intermediates for the preparation of proligestone and related compounds, and new intermediates formed in this process
AU580843B2 (en) * 1985-02-07 1989-02-02 Schering Aktiengesellschaft 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
GB8622330D0 (en) * 1986-09-17 1986-10-22 Erba Farmitalia 4-substituted 6-alkylidenandrostene-3,17-dione derivatives
EP0263569B1 (en) * 1986-10-10 1992-12-09 Roussel-Uclaf 9-alpha-hydroxysteroids, process for their preparation and process for the preparation of the corresponding 9(11)-dehydro-derivatives.
HU203667B (en) * 1986-12-11 1991-09-30 Roussel Uclaf Process for producing synergetic zootechnical compositions containing three components
IE60780B1 (en) * 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
EP0285383B1 (en) * 1987-04-03 1994-03-16 Merck & Co. Inc. Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
EP0334425A1 (en) * 1988-03-24 1989-09-27 Akzo N.V. Novel delta4 - androstene derivatives
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5393785A (en) * 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
PH30747A (en) * 1989-03-10 1997-10-17 Endorech Inc Combination therapy for the treatment of estrogen sensitive disease.
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
KR0181264B1 (ko) * 1989-07-07 1999-03-20 라브리 페르낭 성스테로이드 활성 억제용 안드로겐 유도체
WO1991000731A1 (en) * 1989-07-07 1991-01-24 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions

Also Published As

Publication number Publication date
NZ272841A (en) 1999-06-29
AU5851690A (en) 1991-02-06
MY106725A (en) 1995-07-31
CA2062792A1 (en) 1991-01-08
CA2062792C (en) 2006-03-21
EP0595796A1 (en) 1994-05-11
NZ234417A (en) 1995-10-26
KR920703065A (ko) 1992-12-17
AU6342594A (en) 1994-07-21
ZA905313B (en) 1992-02-26
DE69034035T2 (de) 2004-01-22
IE902458A1 (en) 1991-02-13
ES2189784T3 (es) 2003-07-16
ATE230994T1 (de) 2003-02-15
IL94991A0 (en) 1991-06-10
EP0595796B1 (en) 2003-01-15
US5610150A (en) 1997-03-11
US5593981A (en) 1997-01-14
HU9200048D0 (en) 1992-06-29
WO1991000733A1 (en) 1991-01-24
JPH04506799A (ja) 1992-11-26
AU665311B2 (en) 1995-12-21
HUT60139A (en) 1992-08-28
JP3350048B2 (ja) 2002-11-25
DK0595796T3 (da) 2003-05-05
DE69034035D1 (de) 2003-02-20

Similar Documents

Publication Publication Date Title
US5372996A (en) Method of treatment of androgen-related diseases
US5593981A (en) Method and treatment of androgen-related diseases
US5817649A (en) Combination therapy for the prophylaxis and/or treatment of benign prostatic hyperplasia
US5595985A (en) Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
IE83638B1 (en) Method of treatment of androgen-related diseases
US5550107A (en) Combination therapy for the treatment of estrogen-sensitive disease
Moguilewsky et al. Pharmacological and clinical studies of the antiandrogen Anandron
Bhatnagar et al. Aromatase inhibitors in cancer treatment
IE19990531A1 (en) Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
HK1014878A (en) Combinations for prophylaxsis and/or treatment of benign prostatic hyperplasia containing a 17 beta-hydroxy steroid dehydrogenase(17bhsd) inhibitor and at least one further active ingredient
IE84077B1 (en) Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
WO2007031349A1 (en) Use of c3-c10 17alfa-esters of 9,11-dehydrocortexolone as anti-gonadotrophic agents.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed